Ticker Hub
BTAI — AI Analysis & Sentiment
3 recent AI-generated analyses for BTAI. Sentiment and confidence insights updated continuously.
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting
BioXcel Therapeutics' recent financial results reveal a critical cash shortage and unsustainable burn rate, significantly outweighing a speculative...
Mar 27, 2026BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
BioXcel Therapeutics announced a dilutive stock offering to raise $8.0 million, which is a bearish catalyst due to the significant dilution for sha...
Mar 10, 2026BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal
BioXcel Therapeutics has reported positive Phase 2 clinical trial results for BXCL501 in opioid withdrawal treatment, showcasing strong efficacy an...
Mar 5, 2026